A recent study reveals that individuals who come off popular weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise regimens.
Findings released in a major health publication demonstrates that while obese people frequently drop about a fifth of their total mass while on the medication, the weight returns at an average rate of 0.8 kg per month upon discontinuation.
"Users using such medications need to be informed of the potential of quick weight regain when the treatment ends," warns expert Dr. Susan Jebb.
That rate of recovery suggests a return to pre-treatment weight in about 18 months.
Comparing Approaches
The research, which looked at 37 of trials involving over 9,000 of patients, contrasted the effects of the injectable medications with conventional dieting.
Researchers note that individuals who lose weight through lifestyle changes alone usually have a more gradual weight regain—perhaps 0.1 kg a month—after stopping.
Understanding the Quick Rebound
Nutrition scientists propose the mechanism of the jabs is key to understanding the accelerated weight return.
The injections copy a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Long-term administration of the hormone concentrations far above than the body's typical production might result in the system to produce less of its own natural hormone, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this GLP-1 'fix' results in hunger is unsuppressed, making binge eating far more likely."
An Ongoing Condition?
Health authorities suggest the injections for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes.
Many experts contend that, due to the likelihood of relapse, the therapy should be considered life-long.
This perspective is supported by drug manufacturers, who note that the results "highlight the long-term character of obesity," similar to managing conditions like high blood pressure.
Patient Experiences
Individuals who have come off the jabs explain a powerful resurgence of hunger.
"I experienced a switch flipping and you're instantly extremely hungry," said an individual.
This challenge is worsened if users have not established sustainable dietary or behavioural modifications during treatment.
Growing Adoption
Figures indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Use is more common among women than males.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Ultimately, experts caution that while the jabs are potent agents for shedding pounds, they are not a magic cure and maintained weight loss relies on ongoing behavioural management.
